INTEGRATED HORMONAL REGULATION OF THE DISADVANTAGED MYOCARDIUM

$192,987P01FY2016HDNIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications & trials

Paper 37867472 Paper 37128962 Paper 34802149 Paper 32573852 Paper 32358795 Paper 32349577 Paper 32005991 Paper 31161709 Paper 31117055 Paper 30884246 Paper 30707615 Paper 30501875 Paper 30480483 Paper 29791204 Paper 28230167 Paper 28062416 Paper 27817870 Paper 27664264 Paper 27604528 Paper 27291778 Paper 27207517 Paper 27124483 Paper 26873920 Paper 26522092 Paper 26432905 Paper 26428494 Paper 26354842 Paper 26173733 Paper 26139099 Paper 25701524 Paper 25652537 Paper 25140926 Paper 25128174 Paper 25102010 Paper 25101919 Paper 24739824 Paper 24063386 Paper 23908248 Paper 23824958 Paper 23313388 Paper 23074005 Paper 23021335 Paper 22824174 Paper 22703929 Paper 22450853 Paper 22421446 Paper 22399133 Paper 22266330 Paper 22086942 Paper 22051849 Paper 21974928 Paper 21719727 Paper 21447636 Paper 21147149 Paper 20952620 Paper 20933126 Paper 20519318 Paper 20495810 Paper 20484695 Paper 20149453 Paper 19876839 Paper 19876827 Paper 19844898 Paper 19700519 Paper 19398093 Paper 19144891 Paper 18952009 Paper 18625587 Paper 18596274 Paper 18439986 Paper 18196943 Paper 17691927 Paper 17540718 Paper 17374679 Paper 17283226 Paper 17234700 Paper 17122375 Paper 17023664 Paper 16905601 Paper 16690807 Paper 16644906 Paper 16289267 Paper 16049066 Paper 15961538 Paper 15932969 Paper 15879162 Paper 15821258 Paper 15760943 Paper 15749743 Paper 15513961 Paper 15504931 Paper 15371565 Paper 15086473 Paper 14710111 Paper 12775557 Paper 12626668 Paper 12562949 Paper 12217867 Paper 12117725 Paper 11866229

Abstract

Project III is designed to discover mechanisms that underlie the ability of the immature cardiomyocyte to integrate conflicting hormonal signals that determine the final and optimal cardiomyocyte endowment at birth. Fetal cardiomyocyte endowment is important because it determines the relative force that must be generated by each working cell for the life of offspring and it guides the generation of the coronary architecture within the myocardium. In rats, underendowed hearts are more vulnerable to ischemia-reperfusion injury and heart failure. Based on PPG support we have demonstrated that three hormone/growth factors stimulate cardiomyocyte growth in living near term fetuses: insulin-like growth factor-1 (IGF-1), angiotensin II (Ang II) and Cortisol. Two factors inhibit stimulated cardiomyocyte growth: atrial natriuretic peptide and tri-iodo-L-thyronine (T3). For this project we will study the signaling and actions of IGF-1, T3 and Cortisol. We propose 3 aims that will further our understanding of how these hormones work together and how they might be used to augment cardiomyocte numbers in under-endowed growth restricted hearts. Aim 1 (in vitro) will test the hypothesis that the hierarchy of signaling action from IGF-1, Cortisol and T3 is based on signal interactions within the mitogen activated protein kinase (MAPK), extracellular regulatory kinase (ERK) and the phosphoinositol 3 kinase (PI3K) pathways in the near term fetal ovine cardiomyocyte. Aim 2 will test three hypotheses to determine the roles of IGF-1, Taand Cortisol in regulating cardiomyocyte growth and maturation. The aim speculates that phosphorylation of ERK and PI3-K pathway proteins will be down-regulated in cardiomyocytes in response to subnormal T3 levels which will lead to decreased IGF-1 receptors and increased IGF-1 concentrations. Aim 3 (in vivo) will test the hypothesis that exogenous IGF-1 and T3 can be used to augment cardiomyocyte numbers permanently in the fetal myocardium. The outcome of the project will be possible therapies for repairing disadvantaged hearts in the womb.

View original record on NIH RePORTER →